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Methicillin-resistant Staphylococcus aureus (MRSA) carrying the mecC gene (mecC-MRSA) exhibited at 37°C MICs of oxacillin
close to those of methicillin-susceptible S. aureus (MSSA). We investigated whether at this temperature, mecC-MRSA strains
respond to flucloxacillin treatment like MSSA strains, using a rat model of endocarditis. Flucloxacillin (human-like kinetics of
2 g intravenously every 6 h) cured 80 to 100% of aortic vegetations infected with five different mecC-MRSA strains. These results
suggest that mecC-MRSA infections may successfully respond to treatment with -lactams.
Methicillin-resistant Staphylococcus aureus (MRSA), isolatedfor the first time in the 1960s (1), developed resistance
against methicillin and other -lactam antibiotics through the
acquisition of mecA, a gene encoding the penicillin binding pro-
tein 2a (PBP2a) (2). In 2011, a novelmecA homologue,mecC (3),
was identified in bovine and human MRSA isolates (4–8). Al-
though the incidence of mecC-MRSA is low (8–10), these strains
cause severe infections in humans (11, 12).
Most mecC-MRSA isolates exhibit MICs of oxacillin less than
or slightly greater than the MIC breakpoint of a susceptible strain
(2 mg/liter), and no clear distinction from methicillin-suscep-
tible S. aureus (MSSA) isolates can bemade (13, 14). Furthermore,
the activity of the mecC product, namely, PBP2c (15), appears to
be thermosensitive, with a decline at 37°C (16). This raises the
question as to whether mecC-MRSA infections should be consid-
ered like mecA-MRSA infections and treated with vancomycin
(17) or like MSSA infections, generally treated with -lactams,
such as flucloxacillin (18). In this study, we investigated the in vivo
activity of flucloxacillin onmecC-MRSA strains using a rat model
of endocarditis.
Five mecC-MRSA strains, two of animal origin (NCTC 13552
and 1100) and three of human origin (strain 820, from an infected
knee [6], and the urine and screening strains S090 and S129 [19]),
were used. S. aureus strains ATCC 29213 (MSSA) and Mu50
(mecA-MRSA) were used as controls. The MICs of oxacillin and
cefoxitin were determined according to the Clinical and Labora-
tory Standards Institute (CLSI) guidelines (20). The MICs were
interpreted according to the CLSI guidelines after incubation at
30°C and 37°C for 24 h. Population analysis profiles (PAPs) were
performed on agar plates containing 2-fold serial dilutions of ox-
acillin and on oxacillin-free plates, as described previously (21).
Colony numbers were enumerated after 48 h of incubation at
30°C and 37°C.Oxacillin-induced killing was assessed by time-kill
assays using strains NCTC 13552 and S129. The flasks containing
Mueller-Hinton broth supplemented with 2% NaCl were inocu-
lated with 106 CFU/ml of bacteria, exposed to oxacillin (10 mg/
liter), and incubated at 30°C or 37°C. The concentration of oxa-
cillin approximated trough levels in the sera of rats and was either
less than or greater than theMICs for the organismswhen tested at
a temperature of 30°C or 37°C, respectively (see below).
The production of catheter-induced aortic vegetations and the
installation of the infusion pump device to deliver flucloxacillin
were performed in rats as described previously (22, 23). Endocar-
ditis was induced 24 h after catheterization by intravenous (i.v.)
challenge of the animals with 105 CFU of each test mecC-MRSA
strain and the mecA-MRSA Mu50 strain. Therapy with flucloxa-
cillin (human-like kinetics of 2 g i.v. every 6 h) was started 12 h
later and lasted for 3 days. Control rats were sacrificed at the onset
of treatment and treated rats at 8 h after the end of the last antibi-
otic dose. A group of 3 to 4 control animals was also sacrificed at
the same time as the treated animals. After the sacrifice, aortic
valve vegetations were removed and processed as described previ-
ously (24) for colony counts. All protocols for animal studies were
reviewed and approved by the Cantonal Committee on Animal
Experiments of the State of Vaud, Switzerland (permit number
879.9).
MICs are shown in Table 1. All of the mecC-MRSA isolates
were formally resistant to oxacillin at 30°C and susceptible at 37°C
(threshold,2 mg/liter). All but the S820 isolate were resistant to
cefoxitin (threshold,8mg/liter) at both 30°C and 37°C. Figure 1
shows that upon exposure to oxacillin at 30°C, mecC-MRSA iso-
lates exhibited subpopulations of resistant bacteria at concentra-
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tions up to 32 mg/liter. However, these oxacillin-resistant sub-
populations virtually disappeared at 37°C. Moreover, with the
exception of strain NCTC 13552, for which resistant subpopula-
tions emerged on 8-mg/liter oxacillin plates, the remaining four
tested mecC-MRSA isolates displayed a profile similar to that of
MSSA ATCC 29213 (growth at up to 4 mg/liter oxacillin). The
mecA-MRSA Mu50 strain displayed homogeneous resistance to
oxacillin, as reported previously (25). The rate of killing by oxa-
cillin of the selected isolates NCTC 13552 and S129 was also af-
fected by temperature (Fig. 2). After 24 h of incubation at 30°C,
oxacillin did not display any antibacterial activity (Fig. 2A). In
contrast, after 24 h of incubation at 37°C, oxacillin caused a
2-log10 CFU/ml decrease in cell viability (Fig. 2B). The results of
experimental endocarditis are shown in Table 2. Vegetations of
control animals sacrificed at the start of treatmentwere all infected
and contained high (median, 8.5 log10 CFU/g) bacterial counts.
The peak (30min), the trough (6 h) (mean standard deviation),
and the area under the curve values for flucloxacillin in rat serum
were 174  50 mg/liter, 16  5 mg/liter, and 213 mg · h/liter,
respectively. The half-life was ca. 1 h. These values were close to
those reported in humans, i.e., 125 to 154 mg/liter, 14 mg/liter,
178.6 mg · h/liter, and 1 h, respectively (26, 27). Flucloxacillin
sterilized 80 to 100% of vegetations infected with mecC-MRSA
strains and reduced the vegetation counts by 6 log10 CFU/g
compared to those of controls (P  0.005). Bacteria recovered
fromvegetations showedunchanged oxacillin susceptibility. All of
TABLE 1 MICs of oxacillin and cefoxitina
Strain
MIC (mg/liter)
Oxacillin Cefoxitin
30°C 37°C 30°C 37°C
NCTC 13552 8–16 0.5–1 64 8
1100 16 0.5–2 32 8
820 4 0.5–1 8 4
S090 16 1 32 16
S129 16–32 0.5–2 64 16–32
a MICs were determined at least three times independently at the indicated
temperatures in Mueller-Hinton broth supplemented with 2% NaCl.
FIG 1 Phenotypic expression of oxacillin resistance in mecC-MRSA strains
assessed by population analysis. Large inocula (ca. 109 CFU) of the test strains
were spread ontoMueller-Hinton agar plates supplementedwith 2%NaCl and
containing increasing concentrations of oxacillin and on oxacillin-free plates.
The plates were incubated at 30°C (A) or 37°C (B) for 48 h, and then the CFU
were enumerated. Each assay was performed on two to three independent
occasions.
FIG 2 Killing curves of mecC-MRSA isolates NCTC 13552 and S129 by oxa-
cillin (OXA) at a concentration of 10 mg/liter, simulating antibiotic levels
achieved at trough in rat or human serum.The flasks containing the test strains
not exposed (controls) or exposed to OXAwere incubated at 30°C (A) or 37°C
(B) for 24 h. Results are representative of two independent experiments.
TABLE 2 Outcome of 3-day treatment with flucloxacillin of
experimental endocarditis caused by mecC-MRSA isolates
Strain
No. of sterile vegetations/total no. of vegetations
(%; median [range] log10 CFU/g of vegetation) for
treatment group:
Control Flucloxacillina
NCTC 13552 0/5 (0; 8.5 [6.7–8.9]) 10/11 (91b; 2.0 [2.0–2.7])c
1100 0/5 (0; 8.8 [8.1–9.1]) 9/9 (100); 2.0 [2.0–2.0])
820 0/5 (0; 7.7 [6.4–9.0]) 6/8 (75); 2.0 [2.0–4.1])c
S090 0/5 (0; 8.0 [7.6–9.4]) 9/10 (90b; 2.0 [7.0–3.2])c
S129 0/5 (0; 8.7 [8.3–9.1]) 8/10 (80b; 2.0 [2.0–6.0])c
a Simulation in rats of human pharmacokinetics following 2 g i.v. every 6 h.
b P 0.05 compared to untreated controls by Fisher’s exact test.
c P 0.005 compared to untreated controls by Mann-Whitney test.
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the vegetations from control animals sacrificed at the end of treat-
ment were heavily infected (median, 9.8 log10 CFU/g) (data not
shown). Flucloxacillin was totally ineffective against the mecA-
MRSA Mu50 isolate (0/6 [0%] sterile valves).
In the current study, we observed a clear effect of the temper-
ature on the activity of oxacillin against mecC-MRSA isolates in
vitro. Indeed, all five tested mecC-MRSA isolates showed resis-
tance to oxacillin in assays performed at 30°C but were susceptible
at 37°C. These results are in agreement with those of previous
studies with the NCTC 13552 (formerly LGA251) strain (16).
Temperature is known to have an impact in vitro on the suscepti-
bility of heterogeneous mecA-MRSA strains to oxacillin (28–30),
possibly due to PBP2a downregulation (31) or enzymatic inacti-
vation at 37°C (2). Our results indicate that thermosensitive
heterogeneous expression of oxacillin resistance is also present in
mecC-MRSA isolates. However, in contrast withmecA-MRSA iso-
lates, where resistant subpopulations grew on plates containing
1,000 mg/liter oxacillin at 37°C (29), mecC-MRSA isolates
showed no subpopulations emerging on plates containing 32
mg/liter oxacillin. Furthermore, rats with endocarditis induced by
mecC-MRSAwere successfully treatedwith human-like kinetics of
flucloxacillin. We attribute these positive outcomes to the body
temperature (37°C) present in animals with endocarditis (32).
Indeed, at this temperature, the MICs of oxacillin for the tested
isolates were2 mg/liter, and plasma concentrations of flucloxa-
cillin were greater than the MIC of the organisms throughout the
dosing interval.
These data suggest consideration of -lactams as an option for
the treatment of mecC-MRSA infections. However, due to the
presence of heterogeneous oxacillin-resistant subpopulations, al-
beit at low frequency, caution is advised in the use of these drugs.
Indeed, in an analogous situation, resistant subpopulations in
mecA-MRSA strains negatively impacted the -lactam therapy of
MRSA infections (33).
ACKNOWLEDGMENTS
Thisworkwas supported in part by grant 310030-143799/1 from the Swiss
National Science Foundation.
We thank Ariane Deplano, Université Libre de Bruxelles, Brussels,
Belgium, for sending us mecC S. aureus isolates S090 and S129.
We declare no conflicts of interest.
REFERENCES
1. Jevons MP, Coe AW, Parker MT. 1963. Methicillin resistance in staph-
ylococci. Lancet i:904–907.
2. Hartman BJ, Tomasz A. 1984. Low-affinity penicillin-binding protein
associatedwith beta-lactam resistance in Staphylococcus aureus. J Bacteriol
158:513–516.
3. Ito T, Hiramatsu K, Tomasz A, de Lencastre H, Perreten V, Holden
MT, Coleman DC, Goering R, Giffard PM, Skov RL, Zhang K, Westh
H, O’Brien F, Tenover FC, Oliveira DC, Boyle-Vavra S, Laurent F,
Kearns AM, Kreiswirth B, Ko KS, Grundmann H, Sollid JE, John JF, Jr,
Daum R, Soderquist B, Buist G, International Working Group on the
Classification of Staphylococcal Cassette Chromosome Elements (IWG-
SCC). 2012. Guidelines for reporting novel mecA gene homologues. An-
timicrob Agents Chemother 56:4997–4999. http://dx.doi.org/10.1128
/AAC.01199-12.
4. García-Álvarez L, Holden MT, Lindsay H, Webb CR, Brown DF,
Curran MD, Walpole E, Brooks K, Pickard DJ, Teale C, Parkhill J,
Bentley SD, Edwards GF, Girvan EK, Kearns AM, Pichon B, Hill RL,
Larsen AR, Skov RL, Peacock SJ, Maskell DJ, Holmes MA. 2011.
Methicillin-resistant Staphylococcus aureuswith a novelmecA homologue
in human and bovine populations in the UK and Denmark: a descriptive
study. Lancet Infect Dis 11:595–603. http://dx.doi.org/10.1016/S1473
-3099(11)70126-8.
5. Petersen A, Stegger M, Heltberg O, Christensen J, Zeuthen A, Knudsen
LK, Urth T, Sorum M, Schouls L, Larsen J, Skov R, Larsen AR. 2013.
Epidemiology of methicillin-resistant Staphylococcus aureus carrying the
novel mecC gene in Denmark corroborates a zoonotic reservoir with
transmission to humans. ClinMicrobiol Infect 19:E16–E22. http://dx.doi
.org/10.1111/1469-0691.12036.
6. Laurent F, Chardon H, Haenni M, Bes M, Reverdy ME, Madec JY,
Lagier E, Vandenesch F, Tristan A. 2012. MRSA harboring mecA variant
gene mecC, France. Emerg Infect Dis 18:1465–1467. http://dx.doi.org/10
.3201/eid1809.111920.
7. Kriegeskorte A, Ballhausen B, Idelevich EA, Kock R, Friedrich AW,
Karch H, Peters G, Becker K. 2012. Human MRSA isolates with novel
genetic homolog, Germany. Emerg Infect Dis 18:1016–1018. http://dx
.doi.org/10.3201/eid1806.110910.
8. Paterson GK, Harrison EM, Holmes MA. 2014. The emergence of mecC
methicillin-resistant Staphylococcus aureus. Trends Microbiol 22:42–47.
http://dx.doi.org/10.1016/j.tim.2013.11.003.
9. Basset P, Prod’hom G, Senn L, Greub G, Blanc DS. 2013. Very low
prevalence of methicillin-resistant Staphylococcus aureus carrying the
mecC gene inwestern Switzerland. JHosp Infect 83:257–259. http://dx.doi
.org/10.1016/j.jhin.2012.12.004.
10. Paterson GK, Morgan FJ, Harrison EM, Cartwright EJ, Torok ME,
Zadoks RN, Parkhill J, Peacock SJ, Holmes MA. 2014. Prevalence and
characterization of human mecC methicillin-resistant Staphylococcus au-
reus isolates in England. J Antimicrob Chemother 69:907–910. http://dx
.doi.org/10.1093/jac/dkt462.
11. Barraud O, Laurent F, Francois B, Bes M, Vignon P, Ploy MC. 2013.
Severe human bone infection due to methicillin-resistant Staphylococcus
aureus carrying the novel mecC variant. J Antimicrob Chemother 68:
2949–2950. http://dx.doi.org/10.1093/jac/dkt274.
12. García-Garrote F, Cercenado E, Marin M, Bal M, Trincado P, Corre-
doira J, Ballesteros C, Pita J, Alonso P, Vindel A. 2014. Methicillin-
resistant Staphylococcus aureus carrying the mecC gene: emergence in
Spain and report of a fatal case of bacteraemia. J Antimicrob Chemother
69:45–50. http://dx.doi.org/10.1093/jac/dkt327.
13. Fluit AC. 2011. What to do with MRSA with a novel mec gene? Lancet
Infect Dis 11:580–581. http://dx.doi.org/10.1016/S1473-3099(11)70180
-3.
14. Skov R, Larsen AR, Kearns A, Holmes M, Teale C, Edwards G, Hill R.
2014. Phenotypic detection of mecC-MRSA: cefoxitin is more reliable
than oxacillin. J Antimicrob Chemother 69:133–135. http://dx.doi.org/10
.1093/jac/dkt341.
15. Ballhausen B, Kriegeskorte A, Schleimer N, Peters G, Becker K. 2014.
ThemecA homologmecC confers resistance against beta-lactams in Staph-
ylococcus aureus irrespective of the genetic strain background. Antimicrob
Agents Chemother 58:3791–3798. http://dx.doi.org/10.1128/AAC.02731
-13.
16. Kim C, Milheirico C, Gardete S, Holmes MA, Holden MT, de Lencastre
H, Tomasz A. 2012. Properties of a novel PBP2A protein homolog from
Staphylococcus aureus strain LGA251 and its contribution to the beta-
lactam-resistant phenotype. J Biol Chem 287:36854–36863. http://dx.doi
.org/10.1074/jbc.M112.395962.
17. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan
SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA,
Chambers HF. 2011. Clinical practice guidelines by the Infectious Dis-
eases Society of America for the treatment of methicillin-resistant Staph-
ylococcus aureus infections in adults and children: executive summary.
Clin Infect Dis 52:285–292. http://dx.doi.org/10.1093/cid/cir034.
18. Rayner C, Munckhof WJ. 2005. Antibiotics currently used in the treat-
ment of infections caused by Staphylococcus aureus. InternMed J 35(suppl
2):S3–S16.
19. Deplano A, Vandendriessche S, Nonhoff C, Denis O. 2014. Genetic
diversity amongmethicillin-resistant Staphylococcus aureus isolates carry-
ing the mecC gene in Belgium. J Antimicrob Chemother 69:1457–1460.
http://dx.doi.org/10.1093/jac/dku020.
20. Clinical and Laboratory Standards Institute. 2012. Methods for dilution
antimicrobial susceptibility tests for bacteria that grow aerobically; ap-
proved standard. 9th ed. Document M07-A9. Clinical and Laboratory
Standards Institute, Wayne, PA.
21. Que YA, Entenza JM, Francioli P, Moreillon P. 1998. The impact of
-Lactam Treatment of mecC Experimental Endocarditis
April 2015 Volume 59 Number 4 aac.asm.org 2437Antimicrobial Agents and Chemotherapy
penicillinase on cefamandole treatment and prophylaxis of experimental
endocarditis due to methicillin-resistant Staphylococcus aureus. J Infect
Dis 177:146–154. http://dx.doi.org/10.1086/513805.
22. Héraïef E, Glauser MP, Freedman LR. 1982. Natural history of aortic
valve endocarditis in rats. Infect Immun 37:127–131.
23. Fluckiger U, Moreillon P, Blaser J, Bickle M, Glauser MP, Francioli P.
1994. Simulation of amoxicillin pharmacokinetics in humans for the pre-
vention of streptococcal endocarditis in rats. Antimicrob Agents Che-
mother 38:2846–2849. http://dx.doi.org/10.1128/AAC.38.12.2846.
24. Entenza JM, Vouillamoz J, Glauser MP, Moreillon P. 1997. Levofloxacin
versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of exper-
imental endocarditis due tomethicillin-susceptible or -resistant Staphylo-
coccus aureus. Antimicrob Agents Chemother 41:1662–1667.
25. Chung M, Antignac A, Kim C, Tomasz A. 2008. Comparative study of
the susceptibilities of major epidemic clones of methicillin-resistant
Staphylococcus aureus to oxacillin and to the new broad-spectrum cepha-
losporin ceftobiprole. Antimicrob Agents Chemother 52:2709–2717.
http://dx.doi.org/10.1128/AAC.00266-08.
26. Bergan T, Engeset A, Olszewski W, Ostby N, Solberg R. 1986. Extravas-
cular penetration of highly protein-bound flucloxacillin. Antimicrob
Agents Chemother 30:729–732. http://dx.doi.org/10.1128/AAC.30.5.729.
27. Frank U, Schmidt-Eisenlohr E, Schlosser V, Spillner G, Schindler M,
Daschner FD. 1988. Concentrations of flucloxacillin in heart valves and
subcutaneous and muscle tissues of patients undergoing open-heart sur-
gery. Antimicrob Agents Chemother 32:930–931. http://dx.doi.org/10
.1128/AAC.32.6.930.
28. Thornsberry C, Caruthers JQ, Baker CN. 1973. Effect of temperature on
the in vitro susceptibility of Staphylococcus aureus to penicillinase-
resistant penicillins. Antimicrob Agents Chemother 4:263–269. http://dx
.doi.org/10.1128/AAC.4.3.263.
29. Hartman BJ, Tomasz A. 1986. Expression of methicillin resistance in
heterogeneous strains of Staphylococcus aureus. Antimicrob Agents Che-
mother 29:85–92. http://dx.doi.org/10.1128/AAC.29.1.85.
30. Mateos-Mora M, Knapp CC, Washington JA, II. 1988. Characterization
of resistance phenotype and cephalosporin activity in oxacillin-resistant
Staphylococcus aureus. Antimicrob Agents Chemother 32:170–174. http:
//dx.doi.org/10.1128/AAC.32.2.170.
31. Madiraju MV, Brunner DP, Wilkinson BJ. 1987. Effects of temperature,
NaCl, andmethicillin on penicillin-binding proteins, growth, peptidogly-
can synthesis, and autolysis in methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother 31:1727–1733. http://dx.doi.org/10.1128
/AAC.31.11.1727.
32. Wang ML, Zhang Y, Fan M, Guo YJ, Ren WD, Luo EJ. 2013. A rabbit
model of right-sided Staphylococcus aureus endocarditis created with
echocardiographic guidance. Cardiovasc Ultrasound 11:3. http://dx.doi
.org/10.1186/1476-7120-11-3.
33. Chambers HF. 1997. Methicillin resistance in staphylococci: molecular
and biochemical basis and clinical implications. Clin Microbiol Rev 10:
781–791.
Mancini et al.
2438 aac.asm.org April 2015 Volume 59 Number 4Antimicrobial Agents and Chemotherapy
